Welcome to our dedicated page for LB PHARMACEUTICALS SEC filings (Ticker: LBRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on LB PHARMACEUTICALS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into LB PHARMACEUTICALS's regulatory disclosures and financial reporting.
BlackRock, Inc. filed Amendment No. 1 reporting beneficial ownership of 1,796,543 shares of LB Pharmaceuticals Inc. common stock, representing 6.3% of the class as of June 30, 2026. BlackRock reports sole voting power over 1,771,160 shares and sole dispositive power over 1,796,543 shares, with no shared voting or dispositive power. Various underlying clients have rights to dividends or sale proceeds, but no individual client holds more than five percent of LB Pharmaceuticals’ outstanding common shares.
LB Pharmaceuticals Inc. entered into a private placement with institutional investors to sell 3,577,560 shares of common stock and pre-funded warrants to purchase up to 715,513 shares. Shares are priced at $34.94 and the pre-funded warrants at $34.9399 with a de minimis exercise price of $0.0001 per share. The company expects approximately $150.0 million in gross proceeds, before expenses.
The pre-funded warrants are immediately exercisable, do not expire, and include beneficial ownership limits of 4.99% or 9.99%, adjustable up to 19.99% with notice. LB Pharmaceuticals plans to use the proceeds, together with existing cash, to expand development of LB-102 into additional indications, potentially including negative symptoms of schizophrenia and Alzheimer’s disease agitation/psychosis, and for working capital and general corporate purposes. A Registration Rights Agreement requires filing an S-3 resale registration for the shares and warrant shares within 90 days of closing and using reasonable best efforts to obtain effectiveness within 90 days of filing.
On July 28, 2026, LB Pharmaceuticals Inc agreed to a private placement with institutional investors involving 3,577,560 shares of common stock and pre-funded warrants exercisable for up to 715,513 additional shares. Each share is priced at $34.94 and each pre-funded warrant at $34.9399, with a warrant exercise price of $0.0001 per share. The transaction is expected to close on or about July 30, 2026 and is anticipated to generate approximately $150 million in gross proceeds before expenses.
The company plans to use net proceeds, together with existing cash, to expand development of its lead candidate LB-102 into additional indications such as negative symptoms of schizophrenia and Alzheimer’s disease agitation/psychosis, and for working capital and general corporate purposes. The pre-funded warrants are immediately exercisable, do not expire, and include beneficial ownership limits generally set at 4.99% or 9.99%, adjustable up to 19.99% with notice. LB Pharmaceuticals granted investors registration rights requiring an S-3 resale registration filing within 90 days of closing and efforts to keep it effective until the securities can be sold or resold under Rule 144 without restriction.
LB Pharmaceuticals Inc. filed a prospectus supplement to its Form S-1, updating the existing prospectus by incorporating information from a new Current Report on Form 8-K. The update centers on a press release announcing accelerated timing of topline results from the Phase 3 NOVA-2 clinical trial of LB-102 in schizophrenia. The press release, dated July 22, 2026, is incorporated by reference except for its quoted statements. The company’s common stock trades on The Nasdaq Global Market under the symbol LBRX, and the last reported sale price was $32.31 per share on July 21, 2026.
LB Pharmaceuticals Inc. announced that, based on enrollment projections, it now expects topline results from the pivotal Phase 3 NOVA-2 trial of LB-102 in schizophrenia in the first half of 2027, earlier than prior guidance of the second half of 2027, and plans a pre-NDA meeting with the FDA in the second half of 2027.
NOVA-2 is designed to enroll approximately 460 patients across 25 sites in the United States. The company states it remains well capitalized, with a cash runway expected to fund operations into the second quarter of 2029, including planned topline readouts from the Phase 2 ILLUMINATE-1 trial in bipolar depression in the first quarter of 2028 and from a Phase 2 trial in adjunctive major depressive disorder in the first half of 2029.
JPMorgan Chase & Co. reports beneficial ownership of 1,497,293 shares of LB Pharmaceuticals Inc. common stock, representing 5.2% of the outstanding class. The securities are LB Pharmaceuticals common stock with a par value of $0.0001 per share.
JPMorgan has sole voting power over 1,379,375 shares and sole dispositive power over all 1,497,293 shares reported, with no shared voting or dispositive power. The holdings are attributed to subsidiaries including JPMorgan Chase Bank, National Association, and J.P. Morgan Investment Management Inc.
LB Pharmaceuticals Inc filed a prospectus supplement dated June 10, 2026 that incorporates a Form 8-K reporting the resignation of Chief Medical Officer Anna Eramo, M.D., effective June 15, 2026, and her transition to an adviser and consultant through September 15, 2026. The supplement describes a Separation and Consulting Agreement providing consulting services during a three-month Consulting Period, continuation of option vesting per company plans, reimbursement of COBRA healthcare premiums for up to 12 months, payment of base salary on a monthly basis through June 15, 2027, a prorated 100% target annual bonus for 2026, and acceleration such that 66,143 unvested option shares will vest and become exercisable on September 15, 2026. The company states Dr. Eramo’s departure is for personal reasons, is not related to clinical program operations or practices, and is not expected to have a material impact on clinical development activities or disclosed clinical milestones. The prospectus supplement updates the Registration Statement on Form S-1 (Registration No. 333-294900) and should be read with the Prospectus.
LB Pharmaceuticals Inc. announced that Chief Medical Officer Anna Eramo, M.D. resigned her officer role effective June 15, 2026, for personal reasons and will transition to an advisor role. She will continue providing full-time consulting services through September 15, 2026 while the company searches for a replacement.
The company states that her departure is not related to its clinical program operations or practices and does not expect a material impact on clinical development activities or previously disclosed milestones. Existing clinical development and operations teams will keep overseeing ongoing trials.
Under a Separation and Consulting Agreement dated June 8, 2026, if Dr. Eramo serves through the consulting period and complies with her obligations, she will receive her current base salary paid monthly until June 15, 2027, a prorated 2026 target bonus, and accelerated vesting of 66,143 unvested option shares on September 15, 2026. Her other options continue vesting under existing equity plans, and the company will reimburse COBRA healthcare premiums for up to 12 months, subject to earlier termination conditions.
LB Pharmaceuticals Inc filed a prospectus supplement to its Registration Statement on Form S-1 to update the Prospectus with information from a Current Report on June 9, 2026.
The company held its 2026 Annual Meeting on June 3, 2026. Stockholders elected three Class I directors for three-year terms: Robert A. Lenz, M.D., Ph.D. (20,059,577 votes for), Rebecca Luse (18,530,680 votes for), and Ran Nussbaum (18,748,511 votes for). Stockholders also ratified the appointment of BDO USA, P.C. as the independent registered public accounting firm with 23,275,974 votes for.